# Pizarra — PT-pseudo_152344add0f1 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_152344add0f1
Task: 1

Encounter: Urology - outpatient on 06 Jan 2025.
Referrer: Dr. L. Smits (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 70-year-old male
  - PSA: 11.4 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.209 ng/mL²
  - PSA velocity: 2.78 ng/mL/yr
  - Prior PSA: 10.4 ng/mL
  - Prostate volume: 54.66 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.44734785 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 11.4 ng/mL. PI-RADS 5. PSAD 0.21. Prostate volume 55 mL. csPCa 0.45.

Vitals: weight 84 kg, height 178 cm, BMI 26.5, BP 141/79 mmHg, HR 65 bpm. Smoking: Ex-smoker (33 pack-yr, quit 2017).

Chief complaint: Evaluation triggered by a PSA increase to 11.4 ng/mL, which prompted multiparametric MRI.

History: At seventy years of age, this married gentleman shares a home with his partner and previously earned his living as a delivery driver. His initial workup for an elevated PSA began around mid-2023, with serial measurements now tracking upward to 11.4 ng/mL. Urinary function remains largely unaffected; he reports an IPSS score of 2, free from nocturia or a diminished stream. Lifestyle habits include weekend hiking excursions and a modest alcohol intake capped at four units each week. A history of smoking totals 33 pack-years, though he successfully quit in 2017. Mechanical lower back pain currently keeps him in physiotherapy, where six sessions have yielded little relief. Gradual hearing loss over the last ten years means he depends on unambiguous verbal explanations and written notes during visits. He firmly denies any unexplained weight reduction, drenching night sweats, or skeletal discomfort.

Physical examination: DRE — texture: smooth and symmetrically enlarged; mobility: unrestricted; asymmetry: absent. General survey reveals clear pulmonary fields, a regular cardiac rhythm, and a soft, non-tender abdomen. Cognitive status is fully intact, and functional mobility aligns well with his active weekend hiking schedule.

Patient info: delivery driver; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 4 units / week; exercise Hiking on weekends; IPSS score: 2/35 (mild LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.87 +/- 0.07   (95% CI 0.74-1.00)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.07  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.54 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI report describe the lesion size, zone, and comparison against earlier studies?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend and velocity beyond the headline value?
  - previous_notes (get_previous_notes) -> What is the prior management context, including prior grade and surveillance pathway?

This case hinges on the detailed findings from the mpMRI, the PSA trajectory, and the prior management plan to determine the necessity of a biopsy.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which includes PSA (11.4 ng/mL), PI-RADS (5), PSA density (0.209 ng/mL²), and prostate volume (54.66 mL). It cannot account for the clinical context, such as the patient's age (70), the history of smoking, the fact that the prior biopsy was negative, or the specific interpretation of the mpMRI prose.

WHY THE SUGGESTION COULD BE WRONG
The prior suggests a high probability of biopsy (0.87), but the guideline criterion is based on PI-RADS $\ge 3$, which is met (PI-RADS 5). However, the prior does not account for the potential for overdiagnosis, especially given the high csPCa probability (0.447) and the fact that the prior biopsy was negative. The high aleatoric uncertainty (H=0.54) suggests the model struggles with the data distribution, meaning the suggestion might be based on a subset of cases that doesn't apply here.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI report describe the lesion size, zone, and comparison against earlier studies?
psa_trend - What is the serial PSA trend and velocity beyond the headline value?
previous_notes - What is the prior management context, including prior grade and surveillance pathway?
laboratory panel - What are the full laboratory results?
guideline anchor - The guideline constrains the decision by stating that a PI-RADS $\ge 3$ triggers biopsy, which is met by the PI-RADS 5 score.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_152344add0f1", "radiology_report": "Subject: Prostate Multiparametric MRI | Reporting Radiologist | 20 January 2025\n\nClinical Context: Assessment of rising prostate-specific antigen (11.4 ng/mL) alongside clinical suspicion for malignancy.\n\nFindings: The gland occupies 54.66 mL of space. T2-weighted sequences highlight a discrete hypointense focus at the base-to-mid left peripheral zone, spanning roughly 18 × 14 × 12 mm. Diffusion-weighted imaging shows pronounced restriction with a corresponding low apparent diffusion coefficient. Dynamic contrast sequences capture early, focal enhancement compared to adjacent tissue. No extraprostatic extension or seminal vesicle invasion is visible. Pelvic lymph nodes maintain normal size and structure.\n\nImpression: PI-RADS 5 lesion located in the left peripheral zone (base/mid), approximately 18 mm in diameter. Prostate-specific antigen density calculates to 0.209 ng/mL/mL. csPCa predicted probability stands at 0.44734785."}
get_psa_trend
{"case_id": "PT-pseudo_152344add0f1", "psa_trend": [{"date": "Jul 2023", "val": 7.8}, {"date": "Jan 2024", "val": 1.8}, {"date": "Jul 2024", "val": 5.9}, {"date": "Jan 2025", "val": 11.4}]}
get_previous_notes
{"case_id": "PT-pseudo_152344add0f1", "previous_notes": [{"date": "08 Sep 2024", "author": "Dr. L. Smits (GP)", "text": "Recent outpatient review addressed persistently high PSA values, climbing from 10.4 ng/mL last July to 11.4 ng/mL on the latest draw. The gentleman notes slight lower urinary tract symptoms yet explicitly rules out haematuria or skeletal pain. In light of the rising trend and his age, urology clinic assessment alongside multiparametric MRI scheduling was processed."}]}
NOT RETRIEVED
laboratory panel
Left closed because the moderator's agenda did not explicitly require the full laboratory panel, and no information from the retrieved documents raised a specific question requiring it.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- mpMRI report: PI-RADS 5 lesion located in the left peripheral zone, approximately 18 mm in diameter, with diffusion restriction and focal enhancement.
- psa_trend: PSA velocity is high, with a significant rise from 5.9 ng/mL (Jul 2024) to 11.4 ng/mL (Jan 2025).
- guideline anchor: PI-RADS 5 meets the criterion for biopsy (PI-RADS 3 or higher).

AGAINST Sampling this patient now:
- previous_notes: Prior biopsy was None (None · Negative · ASAP/HGPIN · Positive), suggesting a history of negative findings.

WHERE THIS LEANS
The combined evidence strongly supports proceeding with a biopsy due to the high-risk MRI finding (PI-RADS 5) and the concerning PSA velocity, overriding the history of a negative prior biopsy.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (high-risk PI-RADS 5 lesion and high PSA velocity) strongly supports proceeding with a biopsy, despite the history of a negative prior biopsy. The record is sufficient to make a decision, though the full lab panel remains unreviewed.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is supported by the PI-RADS 5 finding from the mpMRI, which meets the guideline criterion for biopsy. This was reinforced by the high PSA velocity, showing a significant rise from 5.9 ng/mL to 11.4 ng/mL. The statistical prior and the guideline criterion converged on a biopsy recommendation, despite the history of a negative prior biopsy.

Variables that carried weight: bx=noted, age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
